Position in PRTA
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$315,890
+$64,210 QoQ
Shares Held
32,499
+23.3% QoQ
Ownership
0.063%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2020
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PRTA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in PRTA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $315,890 | 32,499 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $251,680 | 26,354 | Shares | Sole | 2026-02-06 | |
| 2025-06-30 | $1,278,068 | 210,555 | Shares | Sole | 2025-07-22 | |
| 2024-09-30 | $484,182 | 28,941 | Shares | Sole | 2024-11-05 | |
| 2023-12-31 | $1,266,449 | 34,850 | Shares | Sole | 2024-02-16 | |
| 2023-03-31 | $1,011,132 | 20,861 | Shares | Sole | 2023-05-12 | |
| 2022-03-31 | $1,138,862 | 31,142 | Shares | Sole | 2022-05-11 | |
| 2021-12-31 | $654,994 | 13,259 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $257,211 | 3,611 | Shares | Sole | 2021-11-12 | |
| 2020-12-31 | $181,290 | 15,095 | Shares | Sole | 2021-02-03 | |
| No filing history on record for this holder in this stock. | ||||||